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Biologically active lipids play pivotal roles in acute inflam-matory responses, resolution of inflammation, as well as 
chronic inflammation.1 Chronic inflammation in atherosclerosis 
is driven by persistent lipid overload, immune activation, and 
failed resolution of inflammation. Hypercholesterolemia leads 
to accumulation of LDL (low-density lipoprotein) and its modi-
fied forms in the artery wall, which elicits vascular inflammation 
that promotes subendothelial monocyte-derived macrophage ac-
cumulation. Macrophages that engulf lipids and transform into 
foam cells are the main innate effector cell within atherosclerotic 
plaques. An imbalance between proinflammatory signals and en-
dogenous signals that resolve inflammation will lead to plaque 
destabilization, linked to enhanced smooth muscle cell (SMC) 
apoptosis, secondary necrosis because of impaired apoptotic cell 
clearance and necrotic core expansion.2 Recent advances in the 
field of chronic inflammatory disorders have identified diverse 
functions of lipid mediators, including proinflammatory and an-
ti-inflammatory, as well as proresolving properties. Promising 
findings in animal models of atherosclerosis suggest a possible 
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Objective—Palmitoylethanolamide is an endogenous fatty acid mediator that is synthetized from membrane phospholipids 
by N-acyl phosphatidylethanolamine phospholipase D. Its biological actions are primarily mediated by PPAR-α 
(peroxisome proliferator-activated receptors α) and the orphan receptor GPR55. Palmitoylethanolamide exerts potent 
anti-inflammatory actions but its physiological role and promise as a therapeutic agent in chronic arterial inflammation, 
such as atherosclerosis remain unexplored.
Approach and Results—First, the polarization of mouse primary macrophages towards a proinflammatory phenotype 
was found to reduce N-acyl phosphatidylethanolamine phospholipase D expression and palmitoylethanolamide 
bioavailability. N-acyl phosphatidylethanolamine phospholipase D expression was progressively downregulated in the 
aorta of apolipoprotein E deficient (ApoE−/−) mice during atherogenesis. N-acyl phosphatidylethanolamine phospholipase 
D mRNA levels were also downregulated in unstable human plaques and they positively associated with smooth 
muscle cell markers and negatively with macrophage markers. Second, ApoE−/− mice were fed a high-fat diet for 4 
or 16 weeks and treated with either vehicle or palmitoylethanolamide (3 mg/kg per day, 4 weeks) to study the effects 
of palmitoylethanolamide on early established and pre-established atherosclerosis. Palmitoylethanolamide treatment 
reduced plaque size in early atherosclerosis, whereas in pre-established atherosclerosis, palmitoylethanolamide promoted 
signs of plaque stability as evidenced by reduced macrophage accumulation and necrotic core size, increased collagen 
deposition and downregulation of M1-type macrophage markers. Mechanistically, we found that palmitoylethanolamide, 
by activating GPR55, increases the expression of the phagocytosis receptor MerTK (proto-oncogene tyrosine-protein 
kinase MER) and enhances macrophage efferocytosis, indicative of proresolving properties.
Conclusions—The present study demonstrates that palmitoylethanolamide protects against atherosclerosis by promoting 
an anti-inflammatory and proresolving phenotype of lesional macrophages, representing a new therapeutic approach to 
resolve arterial inflammation.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2018;38:2562-
2575. DOI: 10.1161/ATVBAHA.118.311185.)
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therapeutic exploitation of bioactive lipids for plaque stabiliza-
tion and limiting plaque progression.3,4
Palmitoylethanolamide is an endogenous lipid mediator of 
the N-acylethanolamines (NAE) family, which shares the same 
biosynthetic pathways with the endocannabinoid anandamide.5 
In mice and humans, it is synthesized via hydrolysis of a mem-
brane phospholipid precursor through the catalytic action of 
N-acyl phosphatidylethanolamine phospholipase D (NAPE-
PLD). The subsequent hydrolysis of palmitoylethanolamide to 
palmitic acid and ethanolamine is catalyzed by fatty acid amide 
hydrolase and more specifically by N-acylethanolamine acid 
amidase (NAAA).5 Palmitoylethanolamide is not only pro-
duced in mammals, but it also occurs as a natural compound of 
plant- and animal-derived food sources, such as soybeans and 
chicken egg yolk.6 In contrast to anandamide, palmitoyletha-
nolamide exhibits only weak binding efficacy at the classical 
cannabinoid receptors CB1 and CB2. Instead, the direct mo-
lecular targets that mediate the biological effects of palmitoyle-
thanolamide are PPAR-α (peroxisome proliferator-activated 
receptor α) and the orphan receptor GPR55.7,8 Although the 
precise molecular mechanisms of action of palmitoylethanol-
amide are not fully elucidated, there is an emerging interest into 
its use as potential analgesic, neuroprotective, and anti-inflam-
matory drug.5 So far, clinical data about the therapeutic benefit 
of palmitoylethanolamide for pain treatment are still limited 
because of the small number of clinical studies and patients 
enrolled, but at least they suggest that it is well tolerated.9
Numerous in vitro and in vivo studies have documented an-
ti-inflammatory effects of palmitoylethanolamide in different di-
sease models,5,10 including contact allergic dermatitis,11 colitis,12 
kidney ischemia-reperfusion injury,13 and diabetic retinopathy.14 
The first evidence to support the anti-inflammatory action of pal-
mitoylethanolamide came from a study showing that palmitoyle-
thanolamide suppresses mast cell activation and degranulation.15 
However, palmitoylethanolamide has multiple effects and the 
ability to act on various cell types, including astrocytes, mi-
croglia, and macrophages, making it an attractive therapeutic 
tool to treat pathologies characterized by neurodegeneration and 
inflammation. The neuroprotective and anti-inflammatory effects 
of palmitoylethanolamide are primarily based on the same mo-
lecular mechanism, that is PPAR-α activation, which reduces the 
transcription of proinflammatory genes.7,16
Despite the well-established anti-inflammatory actions 
of palmitoylethanolamide, possible therapeutic benefits in 
preventing atherosclerotic plaque development and arterial 
inflammation have not been studied. Furthermore, the regula-
tion of palmitoylethanolamide metabolism in atherosclerosis 
remains unexplored. This prompted us to investigate how 
atherosclerosis-associated inflammation modulates the bio-
synthesis of palmitoylethanolamide and further to determine 
the effects of chronic systemic administration of palmitoyle-
thanolamide on early plaque formation, as well as on plaque 
progression at more advanced stage in the apolipoprotein E 
deficient (ApoE−/−) mouse model of atherosclerosis.
Materials and Methods
The data that support the findings of this study are available from the 
corresponding author upon reasonable request. Please see the Major 
Resources Table in the online-only Data Supplement for additional 
experimental details.
Mice
Adult C57Bl/6J mice and GPR55 deficient (GPR55−/−) mice on a 
C57Bl/6J background were used to obtain bone marrow-derived mac-
rophages (BMDMs). For the in vivo pharmacological experiment, fe-
male ApoE−/− mice (The Jackson Laboratory) were fed a high-fat diet 
(HFD, TD88137 mod./Western diet, Ssniff Spezialdiäten GmbH, Soest, 
Germany) for 4 or 16 weeks and randomly assigned to receive either 
vehicle or palmitoylethanolamide (3 mg/kg per day, IP, 4 weeks, Tocris 
Bioscience, Bristol, United Kingdom). Vehicle solution contained 5% 
ethanol and 5% Tween-80 in PBS. The dose selection was based on 
previous studies and on our pilot experiment showing that 3 mg/kg of 
palmitoylethanolamide is needed to induce anti-inflammatory effects 
and to promote macrophage polarization towards M2-type phenotype in 
leukocyte-rich lymphoid organs (data not shown).17,18 Mice were group 
housed during the pharmacological experiment to avoid stress caused by 
single housing. Female mice were used because male mice tend to show 
aggressive behavior against their littermates during repeated handling. 
All animal experiments were approved by the local Ethics committee 
(District Government of Upper Bavaria, Germany; License number: 
55.2-1-54- 2532-111-13) and conducted in accordance with the institu-
tional and national guidelines for the care and use of laboratory animals.
Human Endarterectomy Samples
TVS (Tampere Vascular Study) endarterectomy samples were 
obtained from carotid arteries, abdominal aortas, and femoral arteries 
as previously described.19,20 The left internal thoracic artery samples, 
obtained during coronary artery bypass surgery, served as controls. 
Gene expression was analyzed from carotid (n=29), abdominal 
aortic (n=15), and femoral (n=24) plaques (cases), and atheroscle-
rosis-free left internal thoracic arteries (n=28). The expression levels 
were analyzed with Illumina HumanHT-12 v3 Expression BeadChip 
(Illumina).20,21 The study was approved by the Ethics Committee of 
Tampere Hospital District and conducted according to the declaration 
of Helsinki, and the study subjects gave written informed consent.
Bone Marrow-Derived Macrophages
BMDMs were cultured in RPMI (Roswell Park Memorial 
Institute)-1640 medium supplemented with 10% FCS, penicillin 
Nonstandard Abbreviations and Acronyms
BMDM bone marrow-derived mouse macrophages
CCL2 C-C motif chemokine ligand 2
HDL high-density lipoprotein
HFD high-fat diet
ICAM-1 intercellular adhesion molecule 1
IFN-γ interferon-γ
IL4 interleukin 4
iNOS inducible nitric oxide synthase
LDL low-density lipoprotein
MerTK proto-oncogene tyrosine-protein kinase MER
NAAA N-acylethanolamine acid amidase
NAE N-acylethanolamines
NAPE-PLD N-acyl phosphatidylethanolamine phospholipase D
PPAR-α peroxisome proliferator-activated receptor α
PRRT2 proline-rich transmembrane protein 2
SMC smooth muscle cell
SR-BI scavenger receptor class B member 1
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TVS Tampere Vascular Study
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(100 U/mL), streptomycin (100 μg/mL; all Gibco Life Technologies), 
and 10% filtered L-929 cell-conditioned medium as previously 
described.22 For polarization experiments, BMDMs at a confluence of 
80% were washed with PBS and, thereafter, left untreated or stimu-
lated with IFN-γ (interferon-γ; 10 ng/mL, R&D), IL4 (interleukin 4; 
20 ng/mL, Cedarlane Labs), or dexamethasone (20 nmol/L, Sigma-
Aldrich) in 250 µL RPMI medium without any other supplement. 
After 6 hours, cells and their supernatants were harvested and stored 
at −80°C until further analysis.
Measurement of NAE by Liquid 
Chromatography-Tandem Mass Spectrometry
Concentrations of anandamide and palmitoylethanolamide were 
measured in plasma and lipid extracts of aortas23 of ApoE−/− mice 
and in supernatants from BMDMs that were polarized in serum-free 
medium as described above. Samples were allowed to thaw on ice 
water, and 50 μL aliquots were transferred to 1.5 mL centrifugation 
tubes. After adding 300 μL of ice-cold ethyl acetate/hexane (9:1, v/v) 
containing the deuterated NAEs as internal standards, tubes were vor-
texed for 30 seconds and immediately centrifuged for 15 minutes at 
20 000 g at 4°C. The upper organic phase was removed, evaporated to 
dryness under a gentle stream of nitrogen at 37°C, and reconstituted 
in 50 μL acetonitrile/water (1:1, v/v). Concentrations of anandamide 
and palmitoylethanolamide were determined by liquid chromatogra-
phy-multiple reaction monitoring as previously described.24 Values of 
anandamide and palmitoylethanolamide were normalized to the total 
volume of supernatant.
Vascular SMC and Endothelial Cell Culture
Rat aortic vascular SMCs (A7r5, ATCC CRL-1444) were cultured 
in DMEM supplemented with 10% FCS, penicillin (100 U/mL), and 
streptomycin (100 μg/mL). A7r5 cells were serum-starved (0.5 % 
FCS) overnight and then treated with TNF-α (tumor necrosis fac-
tor α; 0.1–50 ng/mL) for 0.5 to 8 hours. Immortalized murine endo-
thelial cells (SVEC, ATCC CRL-2181) were cultured as previously 
described.22 SVECs were left untreated or treated with palmitoyletha-
nolamide (1 μmol/L) for 30 minutes before stimulation with TNF-α 
(10 ng/mL) for 4 hours.
Histology and Immunohistochemistry
For the quantification of lesion size and necrotic core size, aortic 
roots were cut in 5 μm-thick serial cryosections and stained with 
Oil-Red O or hematoxylin and eosin, respectively. In accordance 
with the guidelines for experimental atherosclerosis studies by the 
American Heart Association,25 lesion size was analyzed in a blinded 
manner and quantified as an average of 4 to 5 sections that were 
separated by 100 μm to cover the entire aortic root. For conven-
tional immunohistochemistry, mouse aortic root cryosections and 
human paraffin-embedded atherosclerosis samples were incubated 
with primary antibodies (NAPE-PLD, Mac-2, CD68, and α-smooth 
muscle actin) followed by colorimetric detection with a horse-
radish peroxidase (brown color) or alkaline phosphatase (red color) 
based systems or by fluorometric detection with fluorochrome-
conjugated secondary antibodies. To quantify apoptosis in ather-
osclerotic lesions, aortic root sections were stained with terminal 
deoxynucleotidyl transferase dUTP nick end labeling (DeadEnd, 
Catalog number: G3250, Promega) according to the manufacturer’s 
protocol.
Lipoprotein Profile and Blood Count Analysis
Plasma samples were subjected to fast-performance liquid chro-
matography (gel filtration on a Superose 6 column; GE Healthcare, 
Chicago, IL). Different lipoprotein fractions (VLDL [very-LDL], 
LDL, and HDL [high-density lipoprotein]) were separated and eval-
uated based on flow-through time. Cholesterol levels were quantified 
using an enzymatic assay (Roche) according to the manufacturer’s 
protocol. Freshly obtained EDTA (ethylenediaminetetraacetic acid) 
blood harvested by cardiac puncture was used to analyze leukocyte 
counts using an animal blood counter (scil Vet ABC Hematology 
Analyzer).
Quantitative Real-Time Polymerase Chain Reaction
Total RNA from BMDMs, A7r5 cells, SVECs, or from lysed tissue 
samples was extracted (peqGold Trifast and Total RNA kit, Peqlab, 
and Norgen biotek kit, Catalog number: 48200) and reverse‐tran-
scribed (PrimeScript RT reagent kit, Clontech).22 Real-time poly-
merase chain reaction was performed with the 7900HT Sequence 
Detection System (Applied Biosystems) using the KAPA PROBE 
FAST Universal quantitative polymerase chain reaction kit (Peqlab) 
and predesigned primer and probe mix (TaqMan Gene Expression 
Assays, Life Technologies). Target mRNA expression was normal-
ized to hypoxanthine guanine phosphoribosyl transferase or glyc-
eraldehyde-3-phosphate dehydrogenase, and the fold induction was 
calculated using the comparative ΔCt method and are presented as 
relative transcript levels (2−ΔΔCt).
Western Blotting
Total protein from aortic lysates was extracted using a Norgen Biotek 
kit according to the manufacturer’s protocol (Catalog number: 48200, 
Norgen Biotek Corp). Aliquots of total protein were then size-frac-
tioned by SDS-polyacrylamide gel electrophoresis and transferred 
to nitrocellulose membranes. After blocking for 1 hour in Tris-
buffered saline containing 0.1% Tween 20 and 5% skim milk (Carl 
Roth), membranes were incubated with primary antibodies against 
VCAM-1 (vascular cell adhesion molecule 1), MerTK (proto-onco-
gene tyrosine-protein kinase), or SR-B1 (scavenger receptor class B 
member 1) followed by detection with horseradish peroxidase–conju-
gated secondary antibodies and enhanced chemiluminescence. Target 
protein expression was normalized to glyceraldehyde-3-phosphate 
dehydrogenase to correct for loading.
Adoptive Transfer of Monocytes
Monocytes were isolated from femurs, tibias, and spines of female 
ApoE−/− mice and enriched with a monocyte isolation kit (Miltenyi 
Biotec MACS, Catalog number: 130-100-629). The purity of iso-
lated monocytes was 90.5±2.1 %. Monocytes were then fluorescently 
labeled (eBioscience efluor 670, Catalog number: 65-0840-85) and 
transferred into female ApoE−/− mice (1×106 cells, IP) that were fed 
an HFD and treated with vehicle or palmitoylethanolamide (3 mg/
kg per day) for 4 weeks. After 24 hours, mice were euthanized and 
the transferred monocytes (identified as CD45+, CD11b+, CD115+, 
and efluor 670+) were quantified in the blood, spleen, and aorta by 
flow cytometry.
In Vitro Phagocytosis Assays and Flow Cytometry
BMDMs were treated with palmitoylethanolamide (1 µmol/L) for 
24 hours. After the treatment, cells were washed with PBS and incu-
bated with fluorescent beads (fluoresbrite carboxylate microspheres, 
Catalog number: 15702, Polysciences, Inc) for 15 minutes at 37°C. 
Cells were thereafter stained with fluorochrome-conjugated anti-
bodies against CD11b and F4/80. Phagocytosis was also measured 
using THP-1 monocytes (ATCC TIB-202) that were stained with 
calcein (1 mg/mL, 30 minutes) and treated with a mixture of acti-
nomycin D, camptothecin, cycloheximide, dexamethasone, and eto-
poside to induce apoptosis (Apoptosis Inducer Kit, Abcam, Catalog 
number: ab102480) for 2 hours. BMDMs were incubated with the 
apoptotic THP-1 cells for 30 minutes and then stained as described 
above. In other experiments, cells were additionally stained with 
an unconjugated antibody against SR-B1 or MerTK and subse-
quently with an anti-rabbit or anti-goat antibody conjugated with 
Alexa Fluor488 (Ref: 711-545-152; Jackson ImmunoResearch 
Laboratories). Data were acquired on a fluorescence-activated cell 
sorter Canto II flow cytometer (BD Biosciences) and analyzed with 
FlowJo v10.2 software (FlowJo, LLC). Percentage and mean fluo-
rescence intensity of F4/80 and CD11b positive cells were analyzed 
for efferocytosis efficiency.
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Statistical Analyses
For human atherosclerosis samples, statistical significance of differ-
ences in gene expression was assessed using the nonparametric Mann-
Whitney U test and log-transformed data. Pearson or nonparametric 
Spearman correlation coefficients were calculated for gene associa-
tions based on D’Agostino-Pearson omnibus normality test results. In 
vitro and in vivo mouse data were analyzed by unpaired Student t test, 
1-way ANOVA, or by 2-way ANOVA followed by Bonferroni post 
hoc tests. Data that did not pass D’Agostino and Pearson omnibus K2 
normality test (P<0.05) or had <8 samples per group were analyzed 
using the Mann-Whitney U test or Kruskal-Wallis test. Unpaired t test 
with Welch’s correction was used for data that revealed unequal vari-
ances with the F test (P<0.05). All data are presented as mean±SEM. 
A 2-tailed P<0.05 was considered statistically significant.
Results
Inflammation Reduces Palmitoylethanolamide 
Levels and NAPE-PLD Expression in Mouse  
Primary Macrophages
The production of palmitoylethanolamide has been previ-
ously shown to be compromised in RAW264.7 macrophages 
after a short 6-hour treatment with the bacterial endotoxin 
lipopolysaccharide.26 This was attributable to reduced tran-
scription and bioactivity of NAPE-PLD, the enzyme synthe-
sizing NAEs including palmitoylethanolamide. To investigate 
whether the levels of NAEs are also affected in primary mouse 
macrophages and whether they are dependent on macrophage 
polarity, we treated BMDMs with IFN-γ, IL4, or dexameth-
asone to polarize the cells towards M1-, M2a-, or M2c-type 
phenotype, respectively. Macrophage polarization did not 
affect anandamide levels, whereas palmitoylethanolamide lev-
els were reduced in M1 and M2a macrophages and increased 
in reparative M2c macrophages (Figure 1A). In line with the 
reduced palmitoylethanolamide level, NAPE-PLD expression 
was significantly downregulated in M1-type macrophages 
(Figure 1B). This was accompanied by a drastic induction 
of the palmitoylethanolamide-degrading enzyme NAAA 
(Figure 1C). NAAA expression was also slightly increased 
in M2a-type macrophages (Figure 1C). Providing in vivo 
support for these findings, a previous study has shown that 
HFD-induced inflammation selectively reduces tissue palmi-
toylethanolamide levels in the aorta and visceral adipose tissue 
of ApoE−/− mice, whereas the tissue levels of anandamide and 
oleoylethanolamine are unchanged or increased, if anything.27 
We were, therefore, interested to investigate whether the de-
cline in tissue palmitoylethanolamide levels is paralleled by 
reduced expression of the palmitoylethanolamide-synthetizing 
NAPE-PLD and by increased expression of the palmitoyleth-
anolamide-degrading enzyme NAAA. Interestingly, shifting 
from normal chow diet to atherogenic HFD progressively 
reduced NAPE-PLD expression in ApoE−/− mice with the 
most robust reduction occurring in the aorta (Figure 1D). In 
contrast, no clear pattern of expressional changes was evident 
for NAAA (Figure 1E). Possibly accounting for the robust re-
duction of NAPE-PLD expression in the aorta, we found that 
inflammatory stimulus with TNF-α downregulates NAPE-
PLD expression also in cultured vascular SMCs (Figure I in 
the online-only Data Supplement). These data suggest that the 
decline in tissue palmitoylethanolamide level is mainly caused 
by reduced NAPE-PLD expression and that NAPE-PLD could 
be used as a biomarker for palmitoylethanolamide availability. 
To investigate the localization of NAPE-PLD in atheroscle-
rotic lesions, we performed immunohistochemical staining for 
aortic root sections obtained from ApoE−/− mice. Conventional 
immunohistochemistry confirmed the presence of NAPE-PLD 
in the SMC layer, as well as in the atherosclerotic plaque, par-
ticularly in close proximity to the arterial wall (Figure 1F). 
Double immunofluorescence further revealed that NAPE-
PLD colocalizes with the macrophage marker Mac-2 in the 
lesion (Figure 1G). Collectively, these findings demonstrate 
that proinflammatory stimuli downregulate the expression of 
NAPE-PLD, which in turn, is likely to selectively suppress the 
synthesis and bioavailability of palmitoylethanolamide.
NAPE-PLD Expression Is Reduced in Unstable  
Human Atherosclerotic Plaques
We then analyzed NAPE-PLD expression as a surrogate 
marker of palmitoylethanolamide bioavailability in human 
atherosclerosis. Consistent with the mouse data, NAPE-
PLD was markedly downregulated in human atheroscle-
rotic plaques compared with histologically normal control 
arteries (Figure 2A). Interestingly, further analysis of type 
V and VI lesions revealed that NAPE-PLD transcript levels 
were reduced in unstable advanced plaques compared with 
stable plaques (Figure 2B). Immunohistochemical stainings 
confirmed the expression of NAPE-PLD in human plaques 
(Figure 2C) and also showed that NAPE-PLD distinctly colo-
calizes in CD68-positive monocytes/macrophages (Figure 2D) 
and to a lesser extent in α-smooth muscle actin expressing 
SMCs (Figure 2E). Using previously published gene signa-
tures,22,28 we found that NAPE-PLD correlated negatively 
with macrophage markers and positively with SMC markers 
in carotid plaques (Figure 2F and 2G). In contrast, these gene 
association patterns were less prominent in abdominal and 
femoral plaques (Figures IIA and IC in the online-only Data 
Supplement), which are more fibrotic lesions compared with 
macrophage-rich carotid lesions. No clear-cut correlations be-
tween NAPE-PLD and macrophage and SMC markers were 
observed in control arteries (Figures IIB and ID in the online-
only Data Supplement). The strongest individual correlations 
were observed for the M2-type macrophage markers (SR-BI 
encoded by the SCARB1 gene) and MerTK and for the SMC 
marker PRRT2 (proline-rich transmembrane protein 2; Figure 
III in the online-only Data Supplement). Taken together, the 
NAPE-PLD expression is associated with SMC markers and 
inversely with macrophages markers in the human atheroscle-
rotic plaque, supporting the finding of reduced NAPE-PLD 
transcript levels in unstable advanced lesions.
Chronic Treatment With Palmitoylethanolamide 
Reduces Plaque Formation in Early Atherosclerosis
To assess the therapeutic benefits of palmitoylethanolamide 
on atherosclerotic plaque burden and inflammation during the 
early phases of the disease, ApoE−/− mice were fed an HFD 
for 4 weeks and randomly allocated to receive daily IP injec-
tions of vehicle or palmitoylethanolamide (3 mg/kg). The 
dose selection was based on previous studies and on our pilot 
experiment showing that 3 mg/kg of palmitoylethanolamide 
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is needed to induce anti-inflammatory effects and to pro-
mote macrophage polarization towards M2-type phenotype 
in leukocyte-rich lymphoid organs (data not shown).17,18 
Pharmacokinetic analysis of palmitoylethanolamide tissue 
levels after a single IP injection (3 mg/kg) demonstrated 
that the administration results in a rapid and subtle increase 
in plasma palmitoylethanolamide concentration, which was 
not detectable in aortic tissue (Figure IV in the online-only 
Data Supplement). With the selected dose and dosage reg-
imen, chronic palmitoylethanolamide treatment had no effect 
on body weight or plasma total cholesterol levels (Figure 3A 
and 3B). However, palmitoylethanolamide treatment signifi-
cantly reduced atherosclerotic lesion size at the level of the 
aortic root (Figure 3C and 3D). Because early plaque forma-
tion predominantly relies on monocyte recruitment and accu-
mulation in inflamed arteries, we assessed plaque macrophage 
content by immunohistochemistry and found that palmi-
toylethanolamide-treated mice tended (P=0.05) to have less 
Mac-2-positive cells in the aortic root sections (Figure 3E), 
but the relative plaque macrophage content was unaffected 
(Figure 3F). Furthermore, palmitoylethanolamide treatment 
did not affect total or differential leukocyte counts in the blood 
(Table I in the online-only Data Supplement).
Administration of Palmitoylethanolamide 
Reduces Vascular Inflammation and Promotes 
Plaque Stability in Advanced Atherosclerosis
The atheroprotective effect of palmitoylethanolamide as a 
preventive therapy in early atherosclerosis led us to inves-
tigate whether palmitoylethanolamide treatment could re-
duce disease burden also in established atherosclerosis. To 
this end, ApoE−/− mice were first fed an HFD for 12 weeks 
Figure 1. Proinflammatory stimuli disturb palmitoylethanolamide (PEA) metabolism. A, Quantification of anandamide (AEA) and PEA levels in cell culture 
supernatants of bone marrow-derived macrophages (BMDMs). BMDMs were left untreated (M0) or polarized for 6 h with IFN-γ (interferon-γ), IL4 (interleukin 
4), or dexamethasone (Dexa) and thereafter the supernatants were analyzed for AEA and PEA concentration. B and C, Quantitative polymerase chain reac-
tion (PCR) analysis of N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) and N-acylethanolamine acid amidase expression (NAAA) in polarized 
BMDMs. D and E, Quantitative PCR analysis of NAPE-PLD and NAAA mRNA levels in the aorta, spleen, and bone marrow of ApoE−/− mice fed either a normal 
chow diet or high-fat diet (HFD). F, NAPE-PLD immunostaining (brown color) of aortic root section of chow-fed ApoE−/− mouse. Black arrows indicate NAPE-
PLD-positive cells within atherosclerotic plaque. The dotted line indicates the boundary between the plaque and arterial wall. Scale bar, 50 µm. G, Immuno-
fluorescence staining for NAPE-PLD and Mac-2 in aortic root section of chow-fed ApoE−/− mouse. White arrows indicate NAPE-PLD/Mac-2 double-positive 
cells. Nuclei are stained with DAPI (4’,6-diamidine-2’-phenylindole dihydrochloride). Scale bar, 50 µm. *P<0.05, **P<0.01, and ***P<0.001 vs M0 macrophages 
or chow-fed mice. Data are mean±SEM, n=4–5 per group from female donors. NAE indicates N-acylethanolamines.
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and then treated with palmitoylethanolamide for 4 weeks 
in parallel with HFD. Similarly to the early atherosclerosis 
model, palmitoylethanolamide administration did not affect 
body weight, plasma total cholesterol, or blood leukocyte 
counts (Figure 4A and 4B; Table I in the online-only Data 
Supplement). Given that PPAR-α activation with established 
therapies, such as fibrates are known to increase plasma 
HDL level while modestly reducing LDL cholesterol,29 we 
further analyzed the plasma lipoprotein profile in palmi-
toylethanolamide-treated mice. However, no changes were 
noted in plasma VLDL, LDL, or HDL cholesterol fractions 
(Figure 4C and 4D). In contrast to the effects in early ath-
erosclerosis, palmitoylethanolamide treatment did not limit 
atherosclerotic plaque size in the aortic root (Figure 4E 
and 4F), but it significantly reduced macrophage accumu-
lation in the lesions (Figure 4G). Plaque SMC content was 
Figure 2. The expression of the palmitoylethanolamide (PEA)-producing enzyme N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) is down-
regulated in unstable human atherosclerotic plaques. A, NAPE-PLD expression (brown color) in atherosclerosis-free control arteries (left internal thoracic 
artery; LITA) and in endarterectomy samples from the carotid artery, abdominal aorta, and femoral artery. B, NAPE-PLD expression in stable and unstable 
plaque phenotypes in a subgroup of advanced plaques (stage V and VI). Exact P values are given in the graphs. C, NAPE-PLD immunostaining of carotid 
endarterectomy sample. D and E, Immunofluorescence staining for NAPE-PLD and CD68 or α-smooth muscle actin (α-SMA). Nuclei are stained with DAPI 
(4’,6-diamidine-2’-phenylindole dihydrochloride). Scale bars, 500 and 50 µm. F and G, Correlation between NAPE-PLD mRNA levels and established M1/
M2 macrophage and smooth muscle cell (SMC) markers in carotid endarterectomy samples (n=29). Spearman correlation coefficient (r) values are shown. 
*P<0.05 and **P<0.01 for correlation significances. CCL indicates C-C motif chemokine ligand; IL, interleukin; IFN, interferon; and TNF, tumor necrosis factor.
2568  Arterioscler Thromb Vasc Biol  November 2018
unaffected by palmitoylethanolamide treatment (Figure V in 
the online-only Data Supplement). Further analysis of plaque 
composition revealed that palmitoylethanolamide treatment 
increased plaque collagen content and reduced necrotic core 
size (Figure 4H and 4I), indicative of more stable plaques. 
Taken together, these data indicate that palmitoylethanol-
amide restrains plaque progression in advanced atheroscle-
rosis without affecting plasma cholesterol levels.
In agreement with the established anti-inflammatory 
actions of palmitoylethanolamide, gene expression analysis 
of aortic lysates showed reduced mRNA levels of proinflam-
matory cytokines and adhesion molecules in palmitoyletha-
nolamide-treated mice (Figure 5A). Specifically, ICAM-1 
(intercellular adhesion molecule 1) and VCAM-1 mRNA 
levels were reduced in the aorta of palmitoylethanolamide-
treated mice (Figure 5A). The reduction of VCAM-1 ex-
pression was also evident at the protein level (Figure 5B and 
5C). Furthermore, iNOS (inducible nitric oxide synthase) 
and CCL2 (C-C motif chemokine ligand 2), phenotypic 
markers of M1-type macrophages, were downregulated by 
palmitoylethanolamide treatment (Figure 5A). We also con-
ducted in vitro experiments with endothelial cells and found 
that palmitoylethanolamide treatment–reduced VCAM-1 and 
CCL2 mRNA expression in TNF-α-stimulated cells, sug-
gesting that the therapeutic effects of palmitoylethanolamide 
are not only mediated by macrophages but also by endothe-
lial cells (Figure VI in the online-only Data Supplement). In 
line with reduced vascular inflammation, adoptive transfer of 
monocytes into vehicle or palmitoylethanolamide-pretreated 
ApoE−/− mice revealed a lower number of the transferred 
monocytes remaining in the blood of palmitoylethanolamide-
treated mice 24 hours after cell transfer. This was paralleled 
with a more increased accumulation of injected monocytes in 
the spleen, whereas we unexpectedly did not find differences 
in aortas (Figure VII in the online-only Data Supplement). We 
may speculate that adoptively transferred monocytes prefer-
entially home to the spleen and that this effect is more pro-
nounced in palmitoylethanolamide-treated mice, which have 
a less inflamed arterial endothelium. To identify whether the 
downregulation of iNOS is localized to macrophages, we did 
Figure 3. Chronic treatment with palmitoylethanolamide (PEA) limits early plaque formation in atherosclerotic ApoE−/− mice. Body weight development (A) and 
plasma cholesterol levels (B) in vehicle- and PEA-treated mice. C, Representative Oil-Red-O and Mac-2-stained aortic root sections. Scale bar, 200 μm. The 
quantification of total plaque area (D), as well as absolute (E) and relative (F) Mac-2 positive area in aortic root sections. *P<0.05 vs vehicle treated. Data are 
mean±SEM, n=9–10 mice per group in each graph.
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double immunofluorescence staining with iNOS and Mac-2 
for aortic root sections. Indeed, palmitoylethanolamide-
treated mice had reduced number of iNOS-positive lesional 
macrophages (Figure 5D and 5F). To gain further insights 
into the possible atheroprotective mechanisms, we turned our 
attention to MerTK and SR-BI, which showed the strongest 
association with NAPE-PLD expression in human atheroscle-
rotic plaques. Western blot analysis of aortic lysates revealed 
that MerTK and SR-BI protein expression were increased 
in palmitoylethanolamide-treated mice (Figure 5B and 5C). 
MerTK is expressed predominantly by M2-type reparative 
macrophages and it mediates phagocytosis of apoptotic cells, 
that is efferocytosis, in atherosclerotic lesion, thus limiting 
the expansion of necrotic core.30–32 We, therefore, quantified 
the number of apoptotic TUNEL+ cells in aortic root lesions. 
In line with the reduced necrotic core and increased MerTK 
Figure 4. Palmitoylethanolamide (PEA) promotes plaque stability in advanced atherosclerosis. Body weight development (A) and plasma total cho-
lesterol levels (B) in vehicle- and PEA-treated ApoE−/− mice after 16 wk of high-fat diet (HFD). n=13–20 mice per group. C, Representative histograms 
high-performance liquid chromatography–fractionated plasma lipoprotein profiles from vehicle- and PEA-treated mice. D, Quantification of plasma VLDL 
(very-low-density lipoprotein), LDL, and HDL (high-density lipoprotein) cholesterol levels in vehicle- and PEA-treated mice. n=4–5 per group after pooling 
of 8–10 samples E, Representative Oil-Red-O, Mac-2, Masson’s trichrome, and hematoxylin and eosin (H&E)-stained aortic root sections. Scale bars, 500 
µm (Oil-Red-O) and 50 µm (Mac-2, Masson’s trichrome, and H&E). Quantification of total plaque area (F) and relative Mac-2 positive-area (G) in aortic root 
sections. Quantification of relative collagen content (H) and necrotic core size (I) in atherosclerotic plaques. F, n=13–18 mice per group; G through I, n=7–10 
mice per group. *P<0.05 and **P<0.01 vs vehicle treated. Data are mean±SEM.
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expression, plaques of palmitoylethanolamide-treated mice 
contained less TUNEL+ cells (Figure 5E and 5G).
Palmitoylethanolamide Increases MerTK 
Expression and Enhances Efferocytosis Through  
the Activation of GPR55
Having noted the therapeutic effect of palmitoylethanolamide 
on plaque necrosis and MerTK expression, we next inves-
tigated whether palmitoylethanolamide directly enhances 
the efferocytotic capacity of macrophages. To address this, 
we first used fluorescently labeled beads and measured the 
efficiency of BMDMs to clear these beads after 24-hour treat-
ment with palmitoylethanolamide. In particular, we studied 
the specific effect of palmitoylethanolamide on macrophages 
that was first polarized to M1, M2a, or M2c-type pheno-
type. Palmitoylethanolamide substantially enhanced phago-
cytosis of fluorescent beads in all BMDM phenotypes with 
the strongest effect appearing in M2c-type macrophages 
(Figure 6A). This effect was evidenced by the increased per-
centage of phagocytotic BMDMs, as well as by the increased 
amount of engulfed beads (ie, mean fluorescence intensity 
of fluorescein isothiocyanate in CD11b+, F4/80high cells; 
Figure 5. Palmitoylethanolamide (PEA) enhances an anti-inflammatory and proresolving plaque phenotype in advanced atherosclerosis. A, Aortic mRNA ex-
pression levels of cytokines and adhesion molecules normalized to hypoxanthine phosphoribosyltransferase and expressed as fold change compared with 
vehicle-treated mice. B, Representative Western blots for MerTK (proto-oncogene tyrosine-protein kinase MER), SR-BI (scavenger receptor class B member 
1), VCAM-1 (vascular cell adhesion molecule 1), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; loading control) in the aortic lysates of vehicle- 
and PEA-treated mice. C, Quantification of aortic MerTK, SR-BI, and VCAM-1 protein expression (normalized to GAPDH). D, Representative double immu-
nofluorescent staining of iNOS (inducible nitric oxide synthase) and Mac-2 in the aortic roots of vehicle- and PEA-treated ApoE−/− mice. Scale bar, 100 μm. 
E, Representative images of aortic root sections in which apoptotic cells were labeled by TUNEL (green) and nuclei by DAPI (4’,6-diamidine-2’-phenylindole 
dihydrochloride; blue). Scale bar, 100 μm. F, Quantification of iNOS-positive macrophage area (% of Mac-2-positive area) in the aortic sinuses. G, Quantifica-
tion of TUNEL+ cells in aortic root plaques of vehicle- and PEA-treated mice. *P<0.05 and **P<0.01 vs vehicle treated. Data are mean±SEM, n=5–13 mice per 
group in each graph. CCL indicates C-C motif chemokine ligand; ICAM, intercellular adhesion molecule 1; IL, interleukin; and TNF, tumor necrosis factor.
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Figure 6B; Figure VIIIC in the online-only Data Supplement). 
Second, BMDMs were incubated with apoptotic THP-1 
monocytes to study the effect of palmitoylethanolamide on 
efferocytosis. Similarly to the phagocytosis of fluorescent 
beads, palmitoylethanolamide-treated macrophages cleared 
more efficiently apoptotic cells, and the effect was most 
prominent in M2c-type macrophages (Figure 6C). We hypoth-
esized that the underlying mechanism for enhanced effero-
cytosis capacity in response to palmitoylethanolamide is a 
direct induction of MerTK expression in macrophages pos-
sibly via GPR55 receptor signaling. To test this hypothesis, 
we used BMDMs derived from wild-type and GPR55−/− mice, 
treated them with palmitoylethanolamide and analyzed the 
expression of MerTK. Quantitative polymerase chain reac-
tion and flow cytometric analyses showed that in wild-type 
cells, palmitoylethanolamide treatment upregulated MerTK 
expression at the mRNA and protein level, whereas in 
GPR55−/− macrophages, these effects were completely absent 
(Figure 6C and 6D). Likewise, GPR55−/− macrophages did 
not show any response to palmitoylethanolamide treatment 
in terms of phagocytosis of fluorescent beads or apoptotic 
THP-1 cells (Figure 6E; Figure IX in the online-only Data 
Supplement). Palmitoylethanolamide also upregulated SR-BI 
mRNA and protein expression in BMDMs, but the effect was 
independent of GPR55 activation (Figure X in the online-
only Data Supplement).
Figure 6. Palmitoylethanolamide (PEA) enhances MerTK (proto-oncogene tyrosine-protein kinase MER) expression and phagocytosis in cultured macro-
phages. A, Representative histograms for phagocytosis of fluorescent beads in control and PEA-treated bone marrow-derived macrophages (BMDMs). Cells 
were first polarized with IFN-γ (interferon-γ), IL4 (interleukin 4), or dexamethasone (Dexa) towards M1-, M2a-, or M2c-type phenotype, respectively, and 
thereafter treated with PEA (1 µmol/L, 24 h) or left untreated. B, Quantification of phagocytosis capacity, expressed as mean fluorescence intensity (MFI) for 
fluorescein isothiocyanate-labeled beads, in M1-, M2a-, and M2c-polarized BMDMs (CD11b+, F4/80high cells). C, Efferocytosis of apoptotic, calcein-stained 
THP-1, expressed as MFI for calcein, in control and PEA-treated macrophages (CD11b+, F4/80high cells). D, Quantitative real-time polymerase chain reaction 
analysis of MerTK mRNA expression in BMDMs derived from GPR55+/+ and GPR55−/− mice. E, Quantification of MerTK surface expression by flow cytometry 
in GPR55+/+ and GPR55−/− BMDMs. F, Quantification of phagocytosis capacity in PEA-treated (1 µmol/L, 24 h) unpolarized GPR55+/+ and GPR55−/− BMDMs. 
*P<0.05 and **P<0.01 vs untreated control. Data are mean±SEM, n=3–6 per group in each graph. Female donors were used except in D through F (see Major 
Resources Table in the online-only Data Supplement for details).
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Discussion
The present study demonstrates that palmitoylethanolamide 
limits atherosclerosis and improves plaque stability. The un-
derlying mechanism is likely to be multifactorial involving 
PPAR-α-mediated anti-inflammation and promotion of pro-
resolving properties of macrophages through the activation 
of GPR55. The clinical relevance of these findings is sup-
ported by the reduced expression of the palmitoylethanol-
amide-synthesizing enzyme NAPE-PLD in unstable human 
plaques. Thus, counteracting the inflammation-driven decline 
in endogenous palmitoylethanolamide level by pharmacolog-
ical means could serve as an intriguing therapeutic strategy 
for atherosclerosis.
Several lines of evidence indicate that inflammation causes 
an imbalance in palmitoylethanolamide metabolism character-
ized by reduced biosynthesis and increased degradation.10,26,33,34 
The ensuing reduction in the bioavailability then dampens 
the counterbalancing effect of palmitoylethanolamide on in-
flammatory processes. Our findings corroborate this concept 
and suggest that changes in palmitoylethanolamide metabo-
lism may occur also in diet-induced inflammation and ather-
osclerosis. We used quantification of NAPE-PLD expression 
as an indirect marker of palmitoylethanolamide bioavaila-
bility, representing a more feasible approach compared with 
mass spectrometric analyses of palmitoylethanolamide level. 
Admittedly, a considerably limitation of this approach is that 
it does not allow concluding that reduced NAPE-PLD expres-
sion is associated with reduced palmitoylethanolamide level. 
Furthermore, the effect on other NAEs, including oleoyleth-
anolamine and anandamide, is unclear. However, studies on 
mice with global and tissue-specific deficiency of NAPE-PLD 
have shown that the gene deletion leads to a marked reduc-
tion in palmitoylethanolamide and oleoylethanolamine levels 
without affecting anandamide level, highlighting the existence 
of alternative synthesis pathways for anandamide.34,35 This 
notion is further supported by the present findings of unal-
tered anandamide levels and significantly reduced palmitoyle-
thanolamide levels in proinflammatory M1-type macrophages. 
Thus, considering that palmitoylethanolamide and oleoyletha-
nolamine both activate PPAR-α and suppress inflammation, 
reduction in their bioavailability is likely to have a parallel 
and synergistic effect on inflammatory signaling. The reduced 
NAPE-PLD expression in unstable advanced plaques and the 
positive association between NAPE-PLD and SMC mark-
ers prompted us to study whether palmitoylethanolamide or 
oleoylethanolamine holds anti-atherosclerotic properties. 
However, considering that the therapeutic potential of palmi-
toylethanolamide has gained wider attention and also fueled 
the development of new pharmaceutical formulations and their 
clinical testing, we chose to administer palmitoylethanolamide 
as therapeutic strategy for atherosclerotic ApoE−/− mice.
Our pharmacokinetic data, revealing a rapid and subtle in-
crease in plasma palmitoylethanolamide concentration, reflect 
the rapid metabolism of palmitoylethanolamide and are in 
line with a previous report on the pharmacokinetic properties 
of palmitoylethanolamide.36 In a mouse model of epilepsy, a 
transient increase of palmitoylethanolamide in the plasma and 
hippocampus was detectable after intraperitoneal injection 
of a much higher palmitoylethanolamide dose (40 mg/kg). 
Unfortunately, it was impossible to detect significant increases 
of palmitoylethanolamide in aortic tissue, likely because of 
the much lower dose used in this study. We may speculate 
that palmitoylethanolamide is rapidly taken up by circulating 
leukocytes and endothelial cells; however, it was technically 
not possible to measure palmitoylethanolamide in cellular 
subfractions of aortas. It needs to be also acknowledged that 
the highest plasma concentration after palmitoylethanolamide 
administration was much lower (<30 nmol/L) than the con-
centration used in in vitro experiments (1 μmol/L).
We found that chronic palmitoylethanolamide treatment 
reduced early atherosclerosis independent of body weight 
and plasma cholesterol level. In the advanced stage of the 
disease, palmitoylethanolamide-reduced plaque inflam-
mation and improved signs of plaque stability. The current 
finding of reduced iNOS, CCL2, ICAM-1, and VCAM-1 
expression in aortas of palmitoylethanolamide-treated mice 
is directly supported by earlier studies showing the same 
effects in various in vitro and in vivo experiments.10 For ex-
ample, a recent study that has the closest relevance to our 
work demonstrated that palmitoylethanolamide, as a combi-
nation treatment with an antioxidant (polydatin), attenuated 
the upregulation of iNOS, VCAM-1, and ICAM-1 associated 
with vascular injury.37 As a major contributing factor in ath-
erogenesis, we found that aortic iNOS expression, as a signa-
ture marker of M1-type macrophages, as well as the number 
of iNOS+ lesional macrophages was reduced by palmitoyle-
thanolamide treatment. Proinflammatory M1 macrophages, 
which outnumber the anti-inflammatory M2 macrophages 
in advanced lesions, feed plaque inflammation by secreting 
cytokines, such as IL6, CCL2, and CCL5.38 Second, palmi-
toylethanolamide treatment increased the aortic expression 
of the phenotypic M2 markers MerTK and SR-BI, support-
ing the shift of plaque macrophages towards an anti-inflam-
matory and proresolving phenotype. Although our in vitro 
experiments with endothelial cells suggest that palmitoyleth-
anolamide may inhibit monocyte recruitment, we could not 
detect a reduced number of adoptively transferred monocyte 
counts in aortas. This might be because of the fact that only 
a minor number of the adoptively transferred monocytes is 
recruited to aortas and consequently small changes might not 
be detectable by flow cytometric analysis of aortic lysates. 
Taken together, the present study further validates the an-
ti-inflammatory effects of palmitoylethanolamide and opens 
a new therapeutic horizon for its applicability in arterial in-
flammation associated with atherosclerosis.
Cholesterol is an important risk factor and driving force 
of atherosclerosis. It also triggers arterial inflammation that 
exacerbates atherosclerosis. Because palmitoylethanolamide 
did not change plasma total cholesterol level or lipoprotein 
profile, the explanation for reduced plaque size and improved 
plaque stability lies in the ability of palmitoylethanolamide 
to locally promote an anti-inflammatory and proresolving 
milieu in the advanced plaque. Palmitoylethanolamide most 
likely and primarily acts on plaque macrophages, which are 
the dominant effector cells in atherosclerosis,38,39 and favor 
their switch to M2-type phenotype. Aside from this notion, 
VCAM-1 and CCL2, which recruit and guide monocytes into 
atherosclerotic plaques, were found to be downregulated in 
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palmitoylethanolamide-treated mice. Supporting these find-
ings, we observed reduced macrophage accumulation in the 
advanced plaques of palmitoylethanolamide-treated mice. 
These data highlight that palmitoylethanolamide is acting lo-
cally on macrophages to induce M2 polarization and possibly 
also on endothelial cells to reduce monocyte entry and conse-
quent macrophage accumulation in the lesions.
Of particular importance, we identified the induction of 
MerTK expression and efferocytosis as a new atheroprotective 
mechanism for palmitoylethanolamide. Mounting in vivo evi-
dence demonstrates that efferocytosis is impaired in advanced 
atherosclerosis, which in turn, aggravates key features of clin-
ically dangerous plaques, including expansion of necrotic 
core and thinning of a fibrous cap that overlies the core.40–42 
Conversely, induction of MerTK and enhanced efferocytosis 
has been linked to resolution of plaque inflammation and to 
stabilization of advanced plaques.30 The in vitro finding that 
palmitoylethanolamide enhances macrophage MerTK expres-
sion and efferocytosis provides a mechanistic explanation for 
the reduced necrotic core size and increased collagen depo-
sition in palmitoylethanolamide-treated ApoE−/−. The pheno-
type of palmitoylethanolamide-treated ApoE−/− mice closely 
resembles a mouse model displaying higher macrophage 
MerTK and improved efferocytosis because of a cleavage-
resistant variant of MerTK.30 Mice with increased macrophage 
MerTK exhibit smaller necrotic cores and increased collagen 
content in atherosclerotic plaques and no change in plaque 
size or in lesional macrophage or SMC numbers. From a drug 
development perspective, measures to enhance MerTK func-
tion and efferocytosis serve as an attractive strategy to prevent 
the progression of plaque necrosis, thus further extending the 
therapeutic repertoire of palmitoylethanolamide.
Using GPR55 deficient macrophages, we were able to 
pinpoint the receptor-level mechanism by which palmitoyle-
thanolamide enhances MerTK expression and efferocytosis. 
Although the nuclear receptor PPAR-α is thought to primarily 
mediate the anti-inflammatory effects of palmitoylethanol-
amide, it seems that palmitoylethanolamide induces MerTK 
expression by activating the orphan receptor GPR55. Despite 
showing a low homology with CB1 and CB2 receptors, 
GPR55 has been introduced as a novel cannabinoid receptor 
that can be directly activated by the endocannabinoids 2-AG 
and anandamide, as well as by low concentrations of palmi-
toylethanolamide.8,43,44 An earlier in vitro study demonstrated 
that selective CB2 receptor activation also improves effero-
cytosis partly through a mechanism involving MerTK induc-
tion.45 However, considering that palmitoylethanolamide has 
only weak affinity for this receptor,46 it is unlikely that palmi-
toylethanolamide shares the same mode of action. This notion 
is supported by the complete lack of MerTK upregulation in 
palmitoylethanolamide-treated GPR55−/− macrophages. In 
contrast, palmitoylethanolamide appeared to upregulate mac-
rophage SR-BI independent of GPR55. This effect might be 
mediated by PPAR-α, which has been previously shown to 
regulate SR-BI in cultured human macrophages and in lesional 
macrophages of ApoE−/− mice.47 SR-BI is a multifunctional 
membrane protein that regulates selective uptake of choles-
terol esters from mature HDL particles in the liver, thus being 
viewed as the HDL receptor.48,49 It also mediates bidirectional 
lipid transport in macrophages.50 Although the physiological 
role of SR-BI in macrophage cholesterol transport is unclear,50 
it is associated with the development of atherosclerosis and 
the risk of coronary heart disease.51 Overexpression of SR-BI 
protects against atherosclerosis,52,53 whereas BM-specific de-
ficiency accelerates atherosclerosis.54,55 Given these charac-
teristics, the induction of SR-BI by palmitoylethanolamide 
might provide additional therapeutic benefits in the treatment 
of atherosclerosis.
In conclusion, the present results demonstrate that the an-
ti-inflammatory potential of palmitoylethanolamide could be 
therapeutically expanded to atherosclerosis, which is char-
acterized by chronic arterial inflammation. In addition to re-
ducing plaque size, we observed that palmitoylethanolamide 
exhibits a plaque-stabilizing effect by increasing collagen 
content and by limiting plaque necrosis. These effects were 
linked to GPR55-mediated enhancement of MerTK expres-
sion and macrophage efferocytosis, which can further amplify 
the anti-inflammatory properties of palmitoylethanolamide 
and hence, synergistically promote resolution of plaque in-
flammation. With the advent of the first clinical outcome data 
on anti-inflammatory therapy in high-risk atherosclerosis 
patients,56 palmitoylethanolamide and its improved formula-
tions represent a new anti-inflammatory treatment option to 
resolve inflammation in atherosclerosis.
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Highlights
• Palmitoylethanolamide-synthesizing enzyme N-acyl phosphatidylethanolamine phospholipase D is downregulated in proinflammatory M1-type 
mouse macrophages and in the aorta of ApoE−/− mice during atherogenesis.
• N-acyl phosphatidylethanolamine phospholipase D expression is also reduced in human atherosclerotic plaques and particularly in advanced 
unstable lesions.
• Chronic palmitoylethanolamide treatment promotes atherosclerotic plaque stability in ApoE−/− mice as evidenced by reduced macrophage ac-
cumulation and necrotic core size, increased collagen deposition and downregulation of M1-type macrophage markers.
• Palmitoylethanolamide induces MerTK (proto-oncogene tyrosine-protein kinase MER) expression and promotes macrophage efferocytosis by 
activating GPR55.
